Annexon

Filter

År

Typ

Språk

2026-01-16 23:05:12 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-01-12 13:00:00 Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 5,56 USD | +5,90%

2026-01-07 22:05:00 Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference 5,53 USD | +8,43%

2025-12-17 01:31:15 Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) 4,90 USD | +2,08%

2025-11-14 22:01:00 Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million 2,71 USD | +1,12%

2025-11-13 04:55:39 Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants 2,68 USD | -5,63%

2025-11-12 22:12:38 Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants 2,84 USD | -4,38%

2025-08-18 22:05:00 Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) 2,35 USD | -3,69%

2025-08-07 22:30:00 Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy 2,37 USD | +0,85%

2025-07-24 13:00:00 Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy 2,55 USD | +2,82%

2025-06-18 22:05:00 Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) 2,34 USD | 0,00%

2025-05-29 22:05:00 Annexon Biosciences to Present at the Jefferies Global Healthcare Conference 2,18 USD | +7,39%

2025-05-19 22:05:00 Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

2025-05-16 22:05:46 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2025-05-12 14:00:00 Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones 1,77 USD | +10,62%

2025-05-09 23:00:00 Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting 1,60 USD | -5,88%

2025-04-16 22:05:18 Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) 1,43 USD | -7,14%

2025-04-08 22:05:00 Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting 1,54 USD | -5,52%

2025-04-04 00:18:29 Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting 1,69 USD | -7,65%

2025-03-17 21:05:37 Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) 2,75 USD | +5,77%

2025-02-26 22:05:00 Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference 2,60 USD | +0,78%

2025-01-10 14:00:00 Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones 4,83 USD | -0,21%

2025-01-07 14:00:00 Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference 5,05 USD | 0,00%

2024-12-16 22:05:00 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) 5,06 USD | +13,96%

2024-12-16 13:30:00 Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) 5,06 USD | +13,96%

2024-12-05 14:00:00 Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting 5,07 USD | -1,74%

2024-11-15 22:59:57 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) 6,12 USD | -3,32%

2024-11-14 14:00:00 Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones 6,33 USD | -3,36%

2024-11-13 22:05:00 Annexon Biosciences to Present at the Jefferies London Healthcare Conference 6,55 USD | -0,91%

2024-10-22 02:00:41 Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting 7,57 USD | +1,20%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Språk